Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioPlus Acquisition's Debt-to-Equity or its related term are showing as below:
BIOSW'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 7.22
Current: 0.04
During the past 2 years, the highest Debt-to-Equity Ratio of BioPlus Acquisition was 7.22. The lowest was 0.02. And the median was 0.02.
BIOSW's Debt-to-Equity is not ranked
in the Diversified Financial Services industry.
Industry Median: 0.18
vs BIOSW: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioPlus Acquisition Debt-to-Equity Related Terms
BioPlus Acquisition Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BioPlus Acquisition's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIOSW vs SBII, GWII, AHPA: Debt-to-Equity Comparison
For the Shell Companies subindustry, BioPlus Acquisition's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPlus Acquisition Debt-to-Equity vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioPlus Acquisition's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPlus Acquisition (BIOSW) has a Debt-to-Equity of 0.04 as of Jun. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioPlus Acquisition and its competitors. This is 100% above median its historical median of 0.02. Over the past decade, BioPlus Acquisition's Debt-to-Equity has ranged from 0.02 to 7.22.
Is BioPlus Acquisition's Debt-to-Equity too high?
BioPlus Acquisition's current Debt-to-Equity of 0.04 is 100% above median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 7.22. The Diversified Financial Services industry median Debt-to-Equity is 0.18. BioPlus Acquisition's value of 0.04 is 77.8% below this industry median. Overall, BioPlus Acquisition has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioPlus Acquisition's Debt-to-Equity compare to SBII and GWII?
BioPlus Acquisition's Debt-to-Equity of 0.04 can be compared against companies in the Diversified Financial Services industry. The industry median Debt-to-Equity is 0.18. BioPlus Acquisition's value of 0.04 is 77.8% below this benchmark. Historically, BioPlus Acquisition's own Debt-to-Equity has ranged from 0.02 to 7.22 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.18, BioPlus Acquisition has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Diversified Financial Services company?
The median Debt-to-Equity among Diversified Financial Services companies is 0.18, based on 171 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPlus Acquisition's current Debt-to-Equity of 0.04 is 77.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioPlus Acquisition and its competitors. For the Diversified Financial Services industry, the median Debt-to-Equity is 0.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPlus Acquisition's current Debt-to-Equity is 0.04, which is 100% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPlus Acquisition stock overvalued right now?
BioPlus Acquisition (BIOSW) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is 100% above median its 10-year median of 0.02 and 77.8% below the Diversified Financial Services industry median of 0.18. BioPlus Acquisition's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioPlus Acquisition (BIOSW), the current Debt-to-Equity is 0.04 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOSW has been successfully added to your 
